Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02812394 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02812394 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT02812394, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will be an open-label, randomized, three-period cross-over pharmacokinetic evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered carbidopa/levodopa, in healthy volunteers.
Interventions
- DRUG CVT-301 (Dose Level 1)
- DRUG CVT-301 (Dose Level 2)
- DRUG Sinemet®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02812394
The ClinicalTrials.gov registry entry for NCT02812394 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CVT-301 (Dose Level 1) is the first listed.
NCT02812394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02812394 about?
NCT02812394 is a clinical study titled "A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets". This study will be an open-label, randomized, three-period cross-over pharmacokinetic evaluation of CVT-301 compared with the Reference Listed Drug (RLD), orally administered carbidopa/levodopa, in healthy volunteers.
What is the current status of trial NCT02812394?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02812394?
The interventions under investigation include: CVT-301 (Dose Level 1) (DRUG), CVT-301 (Dose Level 2) (DRUG), Sinemet® (DRUG).
Who is sponsoring clinical trial NCT02812394?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.